FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Constantine Mitsiades

Research Profile

Disorders

Multiple Myeloma

Chemicals & Drugs

Anatomy

Physiology

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Robert O'Connor; Melissa G Ooi; Paul Richardson; Kenneth Anderson; Martin Clynes; Jake Delmore; Jana Jakubikova; Steffen Klippel; Justine Meiller; Constantine S Mitsiades; Peter O'Gorman
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
Douglas W McMillin; Joseph Negri; Constantine S Mitsiades
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.
Simona Blotta; Teresa Calimeri; Umberto Foresta; Jana Jakubikova; Constantine S Mitsiades; Stefano Molica; Fortunato Morabito; Antonino Neri; Aldo Roccaro; Marco Rossi; Pierosandro Tagliaferri; Pierfrancesco Tassone; Katia Todoerti; Nicola Amodio; Kenneth C Anderson; Abdel Kareem Azab; Nikhil C Munshi
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Constantine Mitsiades (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Robert O'Connor; Melissa G Ooi; Paul Richardson; Kenneth Anderson; Martin Clynes; Jake Delmore; Jana Jakubikova; Steffen Klippel; Justine Meiller; Constantine S Mitsiades; Peter O'Gorman
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
Cancer chemotherapy and pharmacology 2013;71(5):1357-68.
2013: Douglas W McMillin; Joseph Negri; Constantine S Mitsiades
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.
Nature reviews. Drug discovery 2013;12(3):217-28.
2012: Simona Blotta; Teresa Calimeri; Umberto Foresta; Jana Jakubikova; Constantine S Mitsiades; Stefano Molica; Fortunato Morabito; Antonino Neri; Aldo Roccaro; Marco Rossi; Pierosandro Tagliaferri; Pierfrancesco Tassone; Katia Todoerti; Nicola Amodio; Kenneth C Anderson; Abdel Kareem Azab; Nikhil C Munshi
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
Blood 2012;120(25):5002-13.
2012: Steffen Klippel; Jacob Laubach; Douglas W McMillin; Kenneth C Anderson; Jake Delmore; Jana Jakubikova; Efstathios Kastritis; Melissa Ooi; Paul G Richardson; Constantine S Mitsiades
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.
British journal of haematology 2012;159(3):340-51.
2012: Ellen Weisberg; Z Zhao; R Bronson; A L Christie; J F Daley; Ilene Galinsky; James D Griffin; W Hur; Andrew L Kung; Q Liu; Constantine S Mitsiades; Erik Nelson; T Sanda; Martin Sattler; R Smith; Richard M Stone; N Gray
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Leukemia 2012;26(10):2233-44.
2012: Michaela R Reagan; Elizabeth K Sage; F Philipp Seib; Irene M Ghobrial; Sam M Janes; Douglas W McMillin; Constantine S Mitsiades; David L Kaplan
Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ.
Journal of breast cancer 2012;15(3):273-82.
2012: Masahiro Kawahara; Ari Melnick; Constantine S Mitsiades; Ujunwa C Okoye-Okafor; Ashley Pandolfi; Michael Roth; Laura Barreyro; Boris Bartholdy; Maria E Figueroa; Tihomira I Todorova; Britta Will; Ulrich Steidl
H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia.
Cancer cell 2012;22(2):194-208.
2012: Laura Barreyro; Boris Bartholdy; Susana Ben-Neriah; Jacqueline Boultwood; Larry Cripe; Hugo F Fernandez; Peter L Greenberg; Rhett P Ketterling; Constantine S Mitsiades; Cristina Montagna; Elisabeth Paietta; Samir Parekh; Andrea Pellagatti; Robert F Stanley; Christian Steidl; Martin S Tallman; Tihomira I Todorova; Amit Verma; Britta Will; Li Zhou; Ulrich Steidl
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
Blood 2012;120(6):1290-8.
2012: Michael Roth; Guillermo Simkin; Roni Tamari; Amit Verma; Britta Will; Laura Barreyro; Boris Bartholdy; Constantine S Mitsiades; Swathi Narayanagari; Ulrich Steidl
Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.
Blood 2012;120(2):386-94.
2012: Richard J Rickles; Winnie F Tam; Douglas W McMillin; Constantine S Mitsiades; Steffan Nawrocki; Antoaneta Necheva; Laura T Pierce; Kenneth C Anderson; William Avery; Alexis A Borisy; Jennifer Carew; Mei Chen; David Crowe; Melissa Farwell; Francis J Giles; Thomas P Giordano; Vikram Kansra; Margaret S Lee
Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening.
Molecular cancer therapeutics 2012;11(7):1432-42.
2012: Merav Leiba; Constantine S Mitsiades; Arnon Nagler; Mark Pines; Paul G Richardson; Yu-Tzu Tai; Teru Hideshima; Jana Jakubikova; Steffen Klippel; Adi Leiba; Kenneth C Anderson
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
British journal of haematology 2012;157(6):718-31.
2012: Paul G Richardson; Robert L Schlossman; Diane Warren; Kathleen Colson; Deborah Doss; Irene M Ghobrial; Teru Hideshima; Jacob P Laubach; Laura Lunde; Mary McKenney; Constantine S Mitsiades; Nikhil C Munshi; Kimberly Noonan; Katherine C Redman; Kenneth C Anderson
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
European journal of haematology 2012;88(5):446-9.
2012: Shugeng Cao; Jake Delmore; Douglas W McMillin; Constantine S Mitsiades; Giselle Tamayo; Jon Clardy
Inhibition of tumor cells interacting with stromal cells by xanthones isolated from a Costa Rican Penicillium sp.
Journal of natural products 2012;75(4):793-7.
2012: Douglas W McMillin; Kenneth C Anderson; Jake Delmore; Glenn Dranoff; Shohei Koyama; Jacob Laubach; Nikhil C Munshi; Joseph M Negri; Paul G Richardson; Robert L Schlossman; Matthew Vanneman; Constantine S Mitsiades
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.
Blood 2012;119(15):e131-8.
2012: Douglas W McMillin; Kenneth C Anderson; Leutz Buon; Jake E Delmore; Zachary R Hunter; Hannah M Jacobs; Andrew L Kung; Val Monrose; Paul G Richardson; Peter G Smith; Steven P Treon; Jie Yu; Constantine S Mitsiades
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
Molecular cancer therapeutics 2012;11(4):942-51.
2012: Mahmoud R Gaballa; Irene M Ghobrial; Jacob P Laubach; Constantine S Mitsiades; Nikhil Munshi; Kimberly Noonan; Katherine Redman; Kenneth C Anderson; Robert L Schlossman; Paul G Richardson
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Expert review of hematology 2012;5(1):51-66; quiz 67-8.
2012: Niels Wcj van de Donk; Güllü Görgün; Richard Wj Groen; Teru Hideshima; Jana Jakubikova; Jacob Laubach; Henk M Lokhorst; Constantine S Mitsiades; Inger S Nijhof; Reinier A Raymakers; Paul G Richardson; Kenneth C Anderson
Lenalidomide for the treatment of relapsed and refractory multiple myeloma.
Cancer management and research 2012;4():253-68.
2011: Triona Ni Chonghaile; Paul Richardson; Jeremy A Ryan; Stephen E Sallan; Kristopher A Sarosiek; Lewis Silverman; Richard Stone; Yu-Tzu Tai; Anupama Tammareddi; Thanh-Trang Vo; Kenneth C Anderson; Daniel Ruben Carrasco; Daniel J DeAngelo; Jing Deng; Ronny Drapkin; Michelle S Hirsch; Ursula A Matulonis; David J McConkey; Constantine S Mitsiades; Victoria Del Gaizo Moore; Anthony Letai
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
Science (New York, N.Y.) 2011;334(6059):1129-33.
2011: Jacob P Laubach; Marlise R Luskin; Anuj Mahindra; Constantine S Mitsiades; Nikhil C Munshi; Noopur Raje; Kenneth C Anderson; David Avigan; Irene M Ghobrial; Jacalyn Rosenblatt; Robert L Schlossman; Paul G Richardson
Management of relapsed and relapsed/refractory multiple myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(10):1209-16.
2011: Jake E Delmore; Irene M Ghobrial; Timothy Gilpatrick; William C Hahn; Timothy P Heffernan; Ghayas C Issa; Hannah M Jacobs; Efstathios Kastritis; Andrew L Kung; Madeleine E Lemieux; Michael R McKeown; Ronald M Paranal; Jun Qi; Peter B Rahl; Paul G Richardson; Anna C Schinzel; Junwei Shi; Christopher R Vakoc; Richard A Young; Kenneth C Anderson; P Leif Bergsagel; James E Bradner; Marta Chesi; Constantine S Mitsiades
BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Cell 2011;146(6):904-17.
2011: Jana Jakubikova; Kihyun Kim; Steffen Klippel; Merav Leiba; Douglas W McMillin; Kenneth C Anderson; Simona Blotta; David Cervi; Dana Cholujova; John F Daley; Jake Delmore; Teru Hideshima; Sabikun Nahar; Joseph Negri; Melissa Ooi; Paul G Richardson; Jan Sedlak; Constantine S Mitsiades
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.
Haematologica 2011;96(8):1170-9.
2011: Paul G Richardson; Robert L Schlossman; Irene M Ghobrial; Jacob Laubach; Constantine S Mitsiades; Nikhil C Munshi; Kenneth C Anderson
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.
Oncology (Williston Park, N.Y.) 2011;25(7):594, 596.
2011: Constantine S Mitsiades; Faith E Davies; Jacob P Laubach; Douglas Joshua; Kenneth C Anderson; Jesus San Miguel; Paul G Richardson
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(14):1916-23.
2011: Jana Jakubikova; Sophia Adamia; Maria Kost-Alimova; Steffen Klippel; David Cervi; John F Daley; Dana Cholujova; Sun-Young Kong; Merav Leiba; Simona Blotta; Melissa Ooi; Jake Delmore; Jacob Laubach; Paul G Richardson; Jan Sedlak; Kenneth C Anderson; Constantine S Mitsiades
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
Blood 2011;117(17):4409-19.
2011: Sagar Lonial; Constantine S Mitsiades; Paul G Richardson
Treatment options for relapsed and refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(6):1264-77.
2011: Constantine S Mitsiades
How "immunomodulatory" are IMIDs?
Blood 2011;117(5):1440-1.
2011: Meletios-Athanassios Dimopoulos; Constantine S Mitsiades; Kenneth C Anderson; Paul G Richardson
Tanespimycin as antitumor therapy.
Clinical lymphoma, myeloma & leukemia 2011;11(1):17-22.
2011: Jacob P Laubach; Robert Schlossman; Constantine S Mitsiades; Kenneth C Anderson; Paul G Richardson
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Expert review of hematology 2011;4(1):51-60.
2011: Douglas W McMillin; Jake Delmore; Joseph Negri; Leutz Buon; Hannah M Jacobs; Jacob Laubach; Jana Jakubikova; Melissa Ooi; Patrick Hayden; Robert Schlossman; Nikhil C Munshi; Christoph Lengauer; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
British journal of haematology 2011;152(4):420-32.
2011: Paul G Richardson; Constantine S Mitsiades; Jacob P Laubach; Sagar Lonial; Asher Chanan-Khan; Kenneth C Anderson
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
British journal of haematology 2011;152(4):367-79.
2011: Douglas W McMillin; Chandrasekhar V Miduturu; Joseph Negri; Melissa Ooi; Paul G Richardson; Kenneth C Anderson; Jake Delmore; Nathanael S Gray; Steffen Klippel; Andrew L Kung; Constantine S Mitsiades
Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
PloS one 2011;6(7):e20226.
2010: Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David Avigan; Wanling Xie; Irene M Ghobrial; Robert Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie Esseltine; Kenneth C Anderson
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Blood 2010;116(5):679-86.
2010: Paul G Richardson; Asher A Chanan-Khan; Melissa Alsina; Maher Albitar; David Berman; Marianne Messina; Constantine S Mitsiades; Kenneth C Anderson
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.
British journal of haematology 2010;150(4):438-45.
2010: María Victoria Mateos; Maria Teresa Cibeira; Paul G Richardson; Felipe Prosper; Albert Oriol; Javier de la Rubia; Juan José Lahuerta; Ramón García-Sanz; Sonia Extremera; Sergio Szyldergemajn; Claudia Corrado; Harald Singer; Constantine S Mitsiades; Kenneth C Anderson; Joan Bladé; Jesús San Miguel
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(12):3260-9.
2010: Teru Hideshima; Constantine S Mitsiades; Hiroshi Ikeda; Dharminder Chauhan; Noopur Raje; Gullu Gorgun; Hiromasa Hideshima; Nikhil C Munshi; Paul G Richardson; Daniel R Carrasco; Kenneth C Anderson
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.
Blood 2010;115(18):3772-5.
2010: Douglas W McMillin; Jake Delmore; Ellen Weisberg; Joseph M Negri; D Corey Geer; Steffen Klippel; Nicholas Mitsiades; Robert L Schlossman; Nikhil C Munshi; Andrew L Kung; James D Griffin; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
Nature medicine 2010;16(4):483-9.
2009: Melissa G Ooi; Patrick J Hayden; Vassiliki Kotoula; Douglas W McMillin; Elpida Charalambous; Emily Daskalaki; Noopur S Raje; Nikhil C Munshi; Dharminder Chauhan; Teru Hideshima; Leutz Buon; Martin Clynes; Peter O'Gorman; Paul G Richardson; Constantine S Mitsiades; Kenneth C Anderson; Nicholas Mitsiades
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(23):7153-60.
2009: Paul G Richardson; Edie Weller; Sundar Jagannath; David Avigan; Melissa Alsina; Robert Schlossman; Amitabha Mazumder; Nikhil C Munshi; Irene M Ghobrial; Deborah Doss; Diane L Warren; Laura E Lunde; Mary McKenney; Carol Delaney; Constantine S Mitsiades; Teru Hideshima; William Dalton; Robert Knight; Dixie Esseltine; Kenneth C Anderson
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5713-9.
2009: Joseph M Negri; Douglas W McMillin; Jake Delmore; Nicholas Mitsiades; Patrick Hayden; Steffen Klippel; Teru Hideshima; Dharminder Chauhan; Nikhil C Munshi; Carolyn A Buser; John Pollard; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
British journal of haematology 2009;147(5):672-6.
2009: J P Laubach; A Mahindra; Constantine S Mitsiades; R L Schlossman; Nikhil C Munshi; I M Ghobrial; N Carreau; Teru Hideshima; Kenneth C Anderson; Paul G Richardson
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Leukemia 2009;23(12):2222-32.
2009: Constantine S Mitsiades; Kenneth C Anderson
Epigenetic modulation in hematologic malignancies: challenges and progress.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7 Suppl 8():S1-12; quiz S14-6.
2009: Simona Blotta; Pierfrancesco Tassone; Rao H Prabhala; Pierosandro Tagliaferri; David Cervi; Samir Amin; Jana Jakubikova; Yu-Tzu Tai; klaus podar; Constantine S Mitsiades; Alessandro Zullo; Brunella Franco; Kenneth C Anderson; Nikhil C Munshi
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.
Blood 2009;114(15):3276-84.
2009: Jacob P Laubach; Constantine S Mitsiades; Anuj Mahindra; Robert L Schlossman; Teru Hideshima; Dharminder Chauhan; Nicole A Carreau; Irene M Ghobrial; Noopur Raje; Nikhil C Munshi; Kenneth C Anderson; Paul G Richardson
Novel therapies in the treatment of multiple myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(9):947-60.
2009: Eirini Iliaki; Vassiliki Poulaki; Nicholas Mitsiades; Constantine S Mitsiades; Joan W Miller; Evangelos S Gragoudas
Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy.
Investigative ophthalmology & visual science 2009;50(10):4898-904.
2009: Vassiliki Poulaki; Constantine S Mitsiades; Vassiliki Kotoula; Joseph Negri; Ciaran McMullan; Joan W Miller; Paul A Marks; Nicholas Mitsiades
Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Investigative ophthalmology & visual science 2009;50(9):4072-9.
2009: Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Yutaka Okawa; Noopur Raje; klaus podar; Constantine S Mitsiades; Nikhil C Munshi; Paul G Richardson; Ruben D Carrasco; Kenneth C Anderson
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Blood 2009;114(5):1046-52.
2009: Paul G Richardson; Wanling Xie; Constantine S Mitsiades; Asher A Chanan-Khan; Sagar Lonial; Hani Hassoun; David Avigan; Anne Louise Oaklander; David J Kuter; Patrick Y Wen; Santosh kesari; Hannah R Briemberg; Robert Schlossman; Nikhil C Munshi; L Thompson Heffner; Deborah Doss; Dixie Esseltine; Edie Weller; Kenneth C Anderson; Anthony A Amato
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3518-25.
2009: Douglas W McMillin; Melissa Ooi; Jake Delmore; Joseph Negri; Patrick J Hayden; Nicholas Mitsiades; Jana Jakubikova; Sauveur-Michel Maira; Carlos Garcia-Echeverria; Robert Schlossman; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Cancer research 2009;69(14):5835-42.
2009: Mariateresa Fulciniti; Pierfrancesco Tassone; Teru Hideshima; Sonia Vallet; Puru Nanjappa; Seth A Ettenberg; Zhenxin Shen; Nipun Patel; Yu-Tzu Tai; Dharminder Chauhan; Constantine S Mitsiades; Rao H Prabhala; Noopur Raje; Kenneth C Anderson; David R Stover; Nikhil C Munshi
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
Blood 2009;114(2):371-9.
2009: Vassiliki Kotoula; Elias Sozopoulos; Helen Litsiou; Galinos Fanourakis; Triantafyllia Koletsa; Gerassimos Voutsinas; Sofia Tseleni-Balafouta; Constantine S Mitsiades; Axel Wellmann; Nicholas Mitsiades
Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
Endocrine-related cancer 2009;16(2):565-72.
2009: Jacob P Laubach; Constantine S Mitsiades; Aldo Roccaro; Irene M Ghobrial; Kenneth C Anderson; Paul G Richardson
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Leukemia & lymphoma 2009;50(5):694-702.
2009: Constantine S Mitsiades; Teru Hideshima; Dharminder Chauhan; Douglas W McMillin; Steffen Klippel; Jacob P Laubach; Nikhil C Munshi; Kenneth C Anderson; Paul G Richardson
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Seminars in hematology 2009;46(2):166-75.
2009: Constantine S Mitsiades; Cecile Rouleau; Cinara Echart; Krishna Menon; Beverly Teicher; Maria Distaso; Antonio Palumbo; Mario Boccadoro; Kenneth C Anderson; Massimo Iacobelli; Paul G Richardson
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1210-21.
2009: Jacob P Laubach; Constantine S Mitsiades; Teru Hideshima; Robert Schlossman; Dharminder Chauhan; Nikhil Munshi; Irene Ghobrial; Nicole Carreau; Kenneth C Anderson; Paul G Richardson
Bortezomib in the management of multiple myeloma.
Cancer management and research 2009;1():107-17.
2008: Constantine S Mitsiades; Enrique M Ocio; Atanasio Pandiella; Patricia Maiso; Consuelo Gajate; Mercedes Garayoa; David Vilanova; Juan Carlos Montero; Nicholas Mitsiades; Ciaran J McMullan; Nikhil C Munshi; Teru Hideshima; Dharminder Chauhan; Pablo Aviles; Gabriel Otero; Glynn Faircloth; M Victoria Mateos; Paul G Richardson; Faustino Mollinedo; Jesus F San-Miguel; Kenneth C Anderson
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Cancer research 2008;68(13):5216-25.
2008: Paul G Richardson; Constantine S Mitsiades; Robert Schlossman; Irene M Ghobrial; Teru Hideshima; Nikhil C Munshi; Kenneth C Anderson
Bortezomib in the front-line treatment of multiple myeloma.
Expert review of anticancer therapy 2008;8(7):1053-72.
2008: Nikhil C Munshi; Constantine S Mitsiades; Paul G Richardson; Kenneth C Anderson
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma.
Nature clinical practice. Oncology 2008;5(7):374-5.
2008: Masood Ahmad Shammas; H Koley; R C Bertheau; P Neri; M Fulciniti; P Tassone; S Blotta; A Protopopov; Constantine S Mitsiades; Ramesh Babu Batchu; Kenneth C Anderson; A Chin; S Gryaznov; Nikhil C Munshi
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.
Leukemia 2008;22(7):1410-8.
2008: Ellen Weisberg; Renee D Wright; Douglas W McMillin; Constantine S Mitsiades; Arghya Ray; Rosemary Barrett; Sophia Adamia; Richard M Stone; Ilene Galinsky; Andrew L Kung; James D Griffin
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
Molecular cancer therapeutics 2008;7(5):1121-9.
2008: Paul Richardson; Constantine S Mitsiades; Kathleen Colson; Eileen Reilly; Laura McBride; Judy Chiao; Linda Sun; Justin Ricker; Syed Rizvi; Carol Oerth; Barbara Atkins; Ivy Fearen; Kenneth C Anderson; David Siegel
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
Leukemia & lymphoma 2008;49(3):502-7.
2007: Constantine S Mitsiades; Patrick J Hayden; Kenneth C Anderson; Paul G Richardson
From the bench to the bedside: emerging new treatments in multiple myeloma.
Best practice & research. Clinical haematology 2007;20(4):797-816.
2007: Efstathios Kastritis; Constantine S Mitsiades; Meletios A Dimopoulos; Paul G Richardson
Management of relapsed and relapsed refractory myeloma.
Hematology/oncology clinics of North America 2007;21(6):1175-215, x.
2007: Constantine S Mitsiades; Kenneth C Anderson; Daniel R Carrasco
Mouse models of human myeloma.
Hematology/oncology clinics of North America 2007;21(6):1051-69, viii.
2007: Constantine S Mitsiades; Douglas W McMillin; Steffen Klippel; Teru Hideshima; Dharminder Chauhan; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.
Hematology/oncology clinics of North America 2007;21(6):1007-34, vii-viii.
2007: Constantine S Mitsiades; Patrick J Hayden; Vassiliki Kotoula; Douglas W McMillin; Ciaran McMullan; Joseph Negri; Jake E Delmore; Vassiliki Poulaki; Nicholas Mitsiades
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
The Journal of clinical endocrinology and metabolism 2007;92(12):4845-52.
2007: Patrick J Hayden; Constantine S Mitsiades; Kenneth C Anderson; Paul G Richardson
Novel therapies in myeloma.
Current opinion in hematology 2007;14(6):609-15.
2007: Vassiliki Poulaki; Constantine S Mitsiades; Vassiliki Kotoula; Joseph Negri; Douglas W McMillin; Joan W Miller; Nicholas Mitsiades
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Investigative ophthalmology & visual science 2007;48(10):4706-19.
2007: Evdoxia Hatjiharissi; Lian Xu; Daniel Ditzel Santos; Zachary R Hunter; Bryan Ciccarelli; Sigitas Verselis; Michael Modica; Yang Cao; Robert J Manning; Xavier Leleu; Elizabeth A Dimmock; Alexandros Kortsaris; Constantine S Mitsiades; Kenneth C Anderson; Edward A Fox; Steve P Treon
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Blood 2007;110(7):2561-4.
2007: Teru Hideshima; Laurence Catley; Noopur Raje; Dharminder Chauhan; klaus podar; Constantine S Mitsiades; Yu-Tzu Tai; Sonia Vallet; Tanyel Kiziltepe; Enrique M Ocio; Hiroshi Ikeda; Yutaka Okawa; Hiromasa Hideshima; Nikhil C Munshi; Hiroshi Yasui; Paul G Richardson; Kenneth C Anderson
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
British journal of haematology 2007;138(6):783-91.
2007: Teru Hideshima; Constantine S Mitsiades; Giovanni Tonon; Paul G Richardson; Kenneth C Anderson
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Nature reviews. Cancer 2007;7(8):585-98.
2007: Tanyel Kiziltepe; Teru Hideshima; Kenji Ishitsuka; Enrique M Ocio; Noopur Raje; Laurence Catley; Chun-Qi Li; Laura J Trudel; Hiroshi Yasui; Sonia Vallet; Jeffery L Kutok; Dharminder Chauhan; Constantine S Mitsiades; Joseph E Saavedra; Gerald N Wogan; Larry K Keefer; Paul J Shami; Kenneth C Anderson
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.
Blood 2007;110(2):709-18.
2007: Ellen Weisberg; Andrew L Kung; Renee D Wright; Daisy Moreno; Laurence Catley; Arghya Ray; Leigh Zawel; Mary Tran; Jan Cools; Gary Gilliland; Constantine S Mitsiades; Douglas W McMillin; Jingrui Jiang; Elizabeth Hall-Meyers; James D Griffin
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
Molecular cancer therapeutics 2007;6(7):1951-61.
2007: Constantine S Mitsiades; Nicholas Mitsiades; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
Journal of cellular biochemistry 2007;101(4):950-68.
2007: Nikhil C Munshi; Constantine S Mitsiades; Paul G Richardson; Kenneth C Anderson
Does maintenance therapy with thalidomide benefit patients with multiple myeloma?
Nature clinical practice. Oncology 2007;4(7):394-5.
2007: Vassiliki Poulaki; Eirini Iliaki; Nicholas Mitsiades; Constantine S Mitsiades; Yannis Paulus; Deisy V Bula; Evangelos S Gragoudas; Joan W Miller
Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007;21(9):2113-23.
2007: Jooeun Bae; Constantine S Mitsiades; Yu-Tzu Tai; Robert C Bertheau; Masood Ahmad Shammas; Ramesh Babu Batchu; Cheng Li; Laurence Catley; Rao H Prabhala; Kenneth C Anderson; Nikhil C Munshi
Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(12):7730-7.
2007: Joanne Ghobrial; Irene M Ghobrial; Constantine S Mitsiades; Xavier Leleu; Evdoxia Hatjiharissi; Anne-Sophie Moreau; Aldo Roccaro; Robert Schlossman; Teru Hideshima; Kenneth C Anderson; Paul Richardson
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Oncology (Williston Park, N.Y.) 2007;21(7):785-92; discussion 798-800.
2007: Paul G Richardson; Constantine S Mitsiades; Robert Schlossman; Nikhil C Munshi; Kenneth C Anderson
New drugs for myeloma.
The oncologist 2007;12(6):664-89.
2007: Kumar Sukhdeo; Mala Mani; Yunyu Zhang; Jui Dutta; Hiroshi Yasui; Melissa D Rooney; Daniel E Carrasco; Mei Zheng; Haiying He; Yu-Tzu Tai; Constantine S Mitsiades; Kenneth C Anderson; Daniel R Carrasco
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(18):7516-21.
2007: George Mulligan; Constantine S Mitsiades; Bryant Barbara; Fenghuang Zhan; Wee J Chng; Steven Roels; Erik Koenig; Andrew Fergus; Yongsheng Huang; Paul G Richardson; William L Trepicchio; Annemiek Broyl; Pieter Sonneveld; John D Shaughnessy; P Leif Bergsagel; David P Schenkein; Dixie Esseltine; Anthony Boral; Kenneth C Anderson
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Blood 2007;109(8):3177-88.
2007: Constantine S Mitsiades; Joseph Negri; Ciaran McMullan; Douglas W McMillin; Elias Sozopoulos; Galinos Fanourakis; Gerassimos Voutsinas; Sofia Tseleni-Balafouta; Vassiliki Poulaki; David Batt; Nicholas Mitsiades
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Molecular cancer therapeutics 2007;6(3):1070-8.
2007: Irene M Ghobrial; Xavier Leleu; Evdoxia Hatjiharissi; Teru Hideshima; Constantine S Mitsiades; Robert Schlossman; Kenneth C Anderson; Paul Richardson
Emerging drugs in multiple myeloma.
Expert opinion on emerging drugs 2007;12(1):155-63.
2007: Paul G Richardson; Teru Hideshima; Constantine S Mitsiades; Kenneth C Anderson
The emerging role of novel therapies for the treatment of relapsed myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):149-62.
2007: Dharminder Chauhan; Paola Neri; Mugdha Velankar; klaus podar; Teru Hideshima; Mariateresa Fulciniti; Pierfrancesco Tassone; Noopur Raje; Constantine S Mitsiades; Nicholas Mitsiades; Paul Richardson; Leigh Zawel; Mary Tran; Nikhil C Munshi; Kenneth C Anderson
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Blood 2007;109(3):1220-7.
2007: Manuel Aivado; Dimitrios Spentzos; Ulrich Germing; Gil Alterovitz; Xiao-Ying Meng; Franck Grall; Aristoteles Giagounidis; Giannoula Klement; Ulrich Steidl; Hasan H Otu; Akos Czibere; Wolf C Prall; Christof Iking-Konert; Michelle Shayne; Marco F Ramoni; Norbert Gattermann; Rainer Haas; Constantine S Mitsiades; Eric T Fung; Towia Libermann
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(4):1307-12.
2007: Paul G Richardson; Constantine S Mitsiades; Robert Schlossman; Irene M Ghobrial; Teru Hideshima; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
The treatment of relapsed and refractory multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2007;():317-23.
2006: Paul G Richardson; Emily Blood; Constantine S Mitsiades; Sundar Jagannath; Steven R Zeldenrust; Melissa Alsina; Robert Schlossman; S Vincent Rajkumar; K Raman Desikan; Teru Hideshima; Nikhil C Munshi; Kathleen Kelly-Colson; Deborah Doss; Mary L McKenney; Svetlana Gorelik; Diane Warren; Andrea Freeman; Rebecca Rich; Anfang Wu; Marta Olesnyckyj; Kenton Wride; William S Dalton; Jerome B Zeldis; Robert Knight; Edie Weller; Kenneth C Anderson
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Blood 2006;108(10):3458-64.
2006: Paul G Richardson; Constantine S Mitsiades; Nikhil C Munshi; Kenneth C Anderson
Can thalidomide improve outcome in patients with multiple myeloma?
Nature clinical practice. Oncology 2006;3(11):590-1.
2006: Paul G Richardson; Constantine S Mitsiades; Irene M Ghobrial; Kenneth C Anderson
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Current opinion in oncology 2006;18(6):598-608.
2006: Constantine S Mitsiades; Nicholas Mitsiades; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Current drug targets 2006;7(10):1341-7.
2006: Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Dharminder Chauhan; klaus podar; Constantine S Mitsiades; Lenny Dang; Nikhil C Munshi; Paul Richardson; David P Schenkein; Kenneth C Anderson
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5887-94.
2006: Constantine S Mitsiades; Douglas W McMillin; Vassiliki Kotoula; Vassiliki Poulaki; Ciaran McMullan; Joseph Negri; Galinos Fanourakis; Sofia Tseleni-Balafouta; Kenneth B Ain; Nicholas Mitsiades
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
The Journal of clinical endocrinology and metabolism 2006;91(10):4013-21.
2006: Constantine S Mitsiades; John Bogdanos; Dimitrios Karamanolakis; Constantine Milathianakis; Theodoros Dimopoulos; Michael Koutsilieris
Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
Anticancer research 2006;26(5B):3693-700.
2006: Constantine S Mitsiades; Vassiliki Kotoula; Vassiliki Poulaki; Elias Sozopoulos; Joseph Negri; Elpida Charalambous; Galinos Fanourakis; Gerassimos Voutsinas; Sofia Tseleni-Balafouta; Nicholas Mitsiades
Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.
The Journal of clinical endocrinology and metabolism 2006;91(9):3662-6.
2006: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Lenalidomide in multiple myeloma.
Expert review of anticancer therapy 2006;6(8):1165-73.
2006: Reshma Shringarpure; Laurence Catley; Deepak Bhole; Renate Burger; klaus podar; Yu-Tzu Tai; Benedikt Kessler; Paul J Galardy; Hidde L Ploegh; Pierfrancesco Tassone; Teru Hideshima; Constantine S Mitsiades; Nikhil C Munshi; Dharminder Chauhan; Kenneth C Anderson
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
British journal of haematology 2006;134(2):145-56.
2006: Constantine S Mitsiades; Nicholas Mitsiades; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.
European journal of cancer (Oxford, England : 1990) 2006;42(11):1564-73.
2006: Constantine S Mitsiades; Vassiliki Poulaki; Galinos Fanourakis; Elias Sozopoulos; Douglas W McMillin; Zhaoqin Wen; Gerassimos Voutsinas; Sofia Tseleni-Balafouta; Nicholas Mitsiades
Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(12):3705-12.
2006: Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine S Mitsiades; klaus podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Blood 2006;107(10):4053-62.
2006: Constantine S Mitsiades; Nicholas Mitsiades; Ciaran McMullan; Vassiliki Poulaki; Andrew L Kung; Faith E Davies; Gareth Morgan; Masaharu Akiyama; Reshma Shringarpure; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Dharminder Chauhan; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Neal Rosen; Kenneth C Anderson
Antimyeloma activity of heat shock protein-90 inhibition.
Blood 2006;107(3):1092-100.
2006: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Annual review of medicine 2006;57():33-47.
2005: Jing Chen; Benjamin H Lee; Ifor Williams; Jeffery L Kutok; Constantine S Mitsiades; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Sandra Moore; Brian J P Huntly; Doriano Fabbro; Kenneth C Anderson; James D Griffin; D Gary Gilliland
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Oncogene 2005;24(56):8259-67.
2005: Dharminder Chauhan; Laurence Catley; Guilan Li; klaus podar; Teru Hideshima; Mugdha Velankar; Constantine S Mitsiades; Nicholas Mitsiades; Hiroshi Yasui; Anthony Letai; Huib Ovaa; Celia R Berkers; Benjamin Nicholson; Ta-Hsiang Chao; Saskia T C Neuteboom; Paul Richardson; Michael A Palladino; Kenneth C Anderson
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Cancer cell 2005;8(5):407-19.
2005: Paul G Richardson; Robert Schlossman; Constantine S Mitsiades; Teru Hideshima; Nikhil C Munshi; Kenneth C Anderson
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Clinical lymphoma & myeloma 2005;6(2):84-8.
2005: Hiroshi Yasui; Teru Hideshima; Noopur Raje; Aldo Roccaro; Norihiko Shiraishi; Shaji Kumar; Makoto Hamasaki; Kenji Ishitsuka; Yu-Tzu Tai; klaus podar; Laurence Catley; Constantine S Mitsiades; Paul G Richardson; Rainer Albert; Volker Brinkmann; Dharminder Chauhan; Kenneth C Anderson
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Cancer research 2005;65(16):7478-84.
2005: Constantine S Mitsiades; Nicholas Mitsiades
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
Expert review of anticancer therapy 2005;5(3):487-99.
2005: Constantine S Mitsiades; Nicholas Mitsiades; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Expert review of anticancer therapy 2005;5(3):465-76.
2005: Constantine S Mitsiades; Vassiliki Poulaki; Ciaran McMullan; Joseph Negri; Galinos Fanourakis; Athina Goudopoulou; Victoria M Richon; Paul A Marks; Nicholas Mitsiades
Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3958-65.
2005: Teru Hideshima; Dharminder Chauhan; Kenji Ishitsuka; Hiroshi Yasui; Noopur Raje; Shaji Kumar; klaus podar; Constantine S Mitsiades; Hiromasa Hideshima; Lynn Bonham; Nikhil C Munshi; Paul G Richardson; Jack W Singer; Kenneth C Anderson
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Oncogene 2005;24(19):3121-9.
2005: Paul G Richardson; Constantine S Mitsiades
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Future oncology (London, England) 2005;1(2):161-71.
2005: Dharminder Chauhan; Teru Hideshima; Constantine S Mitsiades; Paul Richardson; Kenneth C Anderson
Proteasome inhibitor therapy in multiple myeloma.
Molecular cancer therapeutics 2005;4(4):686-92.
2005: Constantine S Mitsiades
CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
Haematologica 2005;90(4):436-7.
2005: Constantine S Mitsiades; Nicholas Mitsiades
Thyroid carcinoma cells and Fas-mediated apoptosis.
Thyroid : official journal of the American Thyroid Association 2005;15(2):178-9.
2005: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Proteasome inhibition in the treatment of cancer.
Cell cycle (Georgetown, Tex.) 2005;4(2):290-6.
2005: Constantine S Mitsiades; Nicholas Mitsiades; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Proteasome inhibitors as therapeutics.
Essays in biochemistry 2005;41():205-18.
2005: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Novel biological therapies for the treatment of multiple myeloma.
Best practice & research. Clinical haematology 2005;18(4):619-34.
2005: Vassiliki Poulaki; Constantine S Mitsiades; Ciaran McMullan; Galinos Fanourakis; Joseph Negri; Athina Goudopoulou; Ioannis X Halikias; Gerassimos Voutsinas; Sofia Tseleni-Balafouta; Joan W Miller; Nicholas Mitsiades
Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.
Investigative ophthalmology & visual science 2005;46(1):358-66.
2005: Boris Lin; Laurence Catley; Richard LeBlanc; Constantine S Mitsiades; Renate Burger; Yu-Tzu Tai; klaus podar; Markus Wartmann; Dharminder Chauhan; James D Griffin; Kenneth C Anderson
Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.
Blood 2005;105(1):350-7.
2004: Noopur Raje; Shaji Kumar; Teru Hideshima; Kenji Ishitsuka; Dharminder Chauhan; Constantine S Mitsiades; klaus podar; Steven Le Gouill; Paul Richardson; Nikhil C Munshi; David I Stirling; Joseph H Antin; Kenneth C Anderson
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Blood 2004;104(13):4188-93.
2004: Teru Hideshima; klaus podar; Dharminder Chauhan; Kenji Ishitsuka; Constantine S Mitsiades; Yu-Tzu Tai; Makoto Hamasaki; Noopur Raje; Hiromasa Hideshima; George F Schreiner; Aaron N Nguyen; Tony A Navas; Nikhil C Munshi; Paul G Richardson; Linda S Higgins; Kenneth C Anderson
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Oncogene 2004;23(54):8766-76.
2004: Constantine S Mitsiades
Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 4():S23-7.
2004: Constantine S Mitsiades; Nicholas Mitsiades; Nikhil C Munshi; Kenneth C Anderson
Focus on multiple myeloma.
Cancer cell 2004;6(5):439-44.
2004: Dharminder Chauhan; Guilan Li; klaus podar; Teru Hideshima; Constantine S Mitsiades; Robert Schlossman; Nikhil C Munshi; Paul Richardson; Finbarr E Cotter; Kenneth C Anderson
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Blood 2004;104(8):2458-66.
2004: Vassiliki Poulaki; Antonia M Joussen; Nicholas Mitsiades; Constantine S Mitsiades; Eirini Iliaki; Anthony P Adamis
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy.
The American journal of pathology 2004;165(2):457-69.
2004: Paul Richardson; Robert Schlossman; Sundar Jagannath; Melissa Alsina; Raman Desikan; Emily Blood; Edie Weller; Constantine S Mitsiades; Teru Hideshima; Faith Davies; Deborah Doss; Andrea Freeman; Joan Bosch; John Patin; Robert Knight; Jerome B Zeldis; William Dalton; Kenneth C Anderson
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):875-82.
2004: Michael Koutsilieris; Constantine S Mitsiades; John Bogdanos; Theodoros Dimopoulos; Dimitrios Karamanolakis; Constantine Milathianakis; Athanassios Tsintavis
Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4398-405.
2004: Constantine S Mitsiades; Nicholas Mitsiades
CC-5013 (Celgene).
Current opinion in investigational drugs (London, England : 2000) 2004;5(6):635-47.
2004: Constantine S Mitsiades; Nicholas Mitsiades; Michael Koutsilieris
The Akt pathway: molecular targets for anti-cancer drug development.
Current cancer drug targets 2004;4(3):235-56.
2004: Dharminder Chauhan; Guilan Li; Teru Hideshima; klaus podar; Reshma Shringarpure; Constantine S Mitsiades; Nikhil C Munshi; Patricia Yew; Kenneth C Anderson
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
Oncogene 2004;23(20):3597-602.
2004: Yu-Tzu Tai; Laurence Catley; Constantine S Mitsiades; Renate Burger; klaus podar; Reshma Shringpaure; Teru Hideshima; Dharminder Chauhan; Makoto Hamasaki; Kenji Ishitsuka; Paul Richardson; Steve P Treon; Nikhil C Munshi; Kenneth C Anderson
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
Cancer research 2004;64(8):2846-52.
2004: Dharminder Chauhan; Guilan Li; klaus podar; Teru Hideshima; Reshma Shringarpure; Laurence Catley; Constantine S Mitsiades; Nikhil C Munshi; Yu-Tzu Tai; Nanjoo Suh; Gordon W Gribble; Tadashi Honda; Robert Schlossman; Paul Richardson; Michael B. Sporn; Kenneth C Anderson
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Blood 2004;103(8):3158-66.
2004: Panayiotis Karamanakos; Constantine S Mitsiades; PANAGIOTIS E. LEMBESSIS; Michael Kontos; Dimitrios T P Trafalis; Michael Koutsilieris
Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy.
Anticancer research 2004;24(2C):1077-81.
2004: Constantine S Mitsiades; Nicholas Mitsiades; Ciaran McMullan; Vassiliki Poulaki; Reshma Shringarpure; Masaharu Akiyama; Teru Hideshima; Dharminder Chauhan; Marie Joseph; Towia Libermann; Carlos García-Echeverría; Mark A Pearson; Francesco Hofmann; Kenneth C Anderson; Andrew L Kung
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Cancer cell 2004;5(3):221-30.
2004: Dharminder Chauhan; Guilan Li; Daniel Auclair; Teru Hideshima; klaus podar; Nicholas Mitsiades; Constantine S Mitsiades; Lan Bo Chen; Nikhil C Munshi; S Saxena; Kenneth C Anderson
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
Apoptosis : an international journal on programmed cell death 2004;9(2):149-55.
2004: Richard LeBlanc; Teru Hideshima; Laurence Catley; Reshma Shringarpure; Renate Burger; Nicholas Mitsiades; Constantine S Mitsiades; Puneet Cheema; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson; Nikhil C Munshi
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
Blood 2004;103(5):1787-90.
2004: Nikhil C Munshi; Teru Hideshima; Daniel R Carrasco; Masood Ahmad Shammas; Daniel Auclair; Faith Davies; Nicholas Mitsiades; Constantine S Mitsiades; Ryung S. Kim; Cheng Li; S Vincent Rajkumar; Rafael Fonseca; Lief Bergsagel; Dharminder Chauhan; Kenneth C Anderson
Identification of genes modulated in multiple myeloma using genetically identical twin samples.
Blood 2004;103(5):1799-806.
2004: Constantine S Mitsiades; Nicholas Mitsiades; Ciaran McMullan; Vassiliki Poulaki; Reshma Shringarpure; Teru Hideshima; Masaharu Akiyama; Dharminder Chauhan; Nikhil C Munshi; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Victoria M Richon; Paul A Marks; Kenneth C Anderson
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(2):540-5.
2004: Constantine S Mitsiades; PANAGIOTIS E. LEMBESSIS; Antigone Sourla; Constantine Milathianakis; Athanassios Tsintavis; Michael Koutsilieris
Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer.
Clinical & experimental metastasis 2004;21(6):495-505.
2004: Paul G Richardson; Teru Hideshima; Constantine S Mitsiades; Kenneth C Anderson
Proteasome inhibition in hematologic malignancies.
Annals of medicine 2004;36(4):304-14.
2003: Faith E Davies; Ann M Dring; Cheng Li; Andy C Rawstron; Masood Ahmad Shammas; Sheila M O'Connor; James A L Fenton; Teru Hideshima; Dharminder Chauhan; Isabella T Tai; Elizabeth Robinson; Daniel Auclair; Karen Rees; David Gonzalez; A John Ashcroft; Ranjit DasGupta; Constantine S Mitsiades; Nicholas Mitsiades; Lan Bo Chen; Wing H Wong; Nikhil C Munshi; Gareth J Morgan; Kenneth C Anderson
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.
Blood 2003;102(13):4504-11.
2003: Teru Hideshima; Dharminder Chauhan; Toshiaki Hayashi; klaus podar; Masaharu Akiyama; Constantine S Mitsiades; Nicholas Mitsiades; Baoqing Gong; Lynn Bonham; Peter de Vries; Nikhil C Munshi; Paul G Richardson; Jack W Singer; Kenneth C Anderson
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Cancer research 2003;63(23):8428-36.
2003: Teru Hideshima; Dharminder Chauhan; Toshiaki Hayashi; Masaharu Akiyama; Nicholas Mitsiades; Constantine S Mitsiades; klaus podar; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Oncogene 2003;22(52):8386-93.
2003: Vassiliki Poulaki; Constantine S Mitsiades; Ciaran McMullan; Despoina Sykoutri; Galinos Fanourakis; Vassiliki Kotoula; Sofia Tseleni-Balafouta; Demetrios A Koutras; Nicholas Mitsiades
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas.
The Journal of clinical endocrinology and metabolism 2003;88(11):5392-8.
2003: Dharminder Chauhan; Guilan Li; Teru Hideshima; klaus podar; Constantine S Mitsiades; Nicholas Mitsiades; Laurence Catley; Yu-Tzu Tai; Toshiaki Hayashi; Reshma Shringarpure; Renate Burger; Nikhil C Munshi; Yasuyuki Ohtake; Satya Saxena; Kenneth C Anderson
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.
Blood 2003;102(9):3379-86.
2003: Constantine S Mitsiades; Nicholas Mitsiades; Ron T Bronson; Dharminder Chauhan; Nikhil C Munshi; Steve P Treon; Christopher A Maxwell; Linda M Pilarski; Teru Hideshima; Robert M Hoffman; Kenneth C Anderson
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
Cancer research 2003;63(20):6689-96.
2003: Constantine S Mitsiades; Despoina Sykoutri; Ciaran McMullan; Vassiliki Poulaki; Nicholas Mitsiades
Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines.
The Journal of clinical endocrinology and metabolism 2003;88(10):5043-4; author reply 5044.
2003: Dharminder Chauhan; Guilan Li; Martin Sattler; klaus podar; Constantine S Mitsiades; Nicholas Mitsiades; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.
Oncogene 2003;22(40):6296-300.
2003: Yu-Tzu Tai; klaus podar; Laurence Catley; Yu-Hua Tseng; Masaharu Akiyama; Reshma Shringarpure; Renate Burger; Teru Hideshima; Dharminder Chauhan; Nicholas Mitsiades; Paul Richardson; Nikhil C Munshi; C Ronald Kahn; Constantine S Mitsiades; Kenneth C Anderson
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.
Cancer research 2003;63(18):5850-8.
2003: Constantine S Mitsiades; Vassiliki Poulaki; Nicholas Mitsiades
The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer.
The Journal of endocrinology 2003;178(2):205-16.
2003: John Bogdanos; Dimitrios Karamanolakis; Roxane Tenta; Athanassios Tsintavis; Constantine Milathianakis; Constantine S Mitsiades; Michael Koutsilieris
Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.
Endocrine-related cancer 2003;10(2):279-89.
2003: Dharminder Chauhan; Guilan Li; Teru Hideshima; klaus podar; Constantine S Mitsiades; Nicholas Mitsiades; Nikhil C Munshi; Surender Kharbanda; Kenneth C Anderson
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells.
The Journal of biological chemistry 2003;278(20):17593-6.
2003: Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Ciaran McMullan; Vassiliki Poulaki; Galinos Fanourakis; Robert Schlossman; Dharminder Chauhan; Nikhil C Munshi; Teru Hideshima; Victoria M Richon; Paul A Marks; Kenneth C Anderson
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Blood 2003;101(10):4055-62.
2003: Dharminder Chauhan; Guilan Li; Daniel Auclair; Teru Hideshima; Paul Richardson; klaus podar; Nicholas Mitsiades; Constantine S Mitsiades; Cheng Li; Ryung S. Kim; Nikhil C Munshi; Lan Bo Chen; Wing Wong; Kenneth C Anderson
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
Blood 2003;101(9):3606-14.
2003: Constantine S Mitsiades; Nicholas Mitsiades
P2X7 polymorphism and chronic lymphocytic leukaemia.
Lancet 2003;361(9367):1478; author reply 1478-9.
2003: Constantine S Mitsiades; Nicholas Mitsiades; Paul G Richardson; Steve P Treon; Kenneth C Anderson
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Seminars in oncology 2003;30(2):309-12.
2003: Steve P Treon; Abigail Kelliher; Beverly Keele; Stanley Frankel; Christos Emmanouilides; Eva Kimby; Robert Schlossman; Nicholas Mitsiades; Constantine S Mitsiades; Frederic Preffer; Kenneth C Anderson
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
Seminars in oncology 2003;30(2):248-52.
2003: Constantine S Mitsiades; Nicholas Mitsiades; Steve P Treon; Kenneth C Anderson
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias.
Seminars in oncology 2003;30(2):156-60.
2003: Yu-Tzu Tai; klaus podar; Nicholas Mitsiades; Boris Lin; Constantine S Mitsiades; Deepak Gupta; Masaharu Akiyama; Laurence Catley; Teru Hideshima; Nikhil C Munshi; Steve P Treon; Kenneth C Anderson
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.
Blood 2003;101(7):2762-9.
2003: Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Vassiliki Poulaki; Yu-Tzu Tai; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Robert Schlossman; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Blood 2003;101(6):2377-80.
2003: Teru Hideshima; Constantine S Mitsiades; Masaharu Akiyama; Toshiaki Hayashi; Dharminder Chauhan; Paul Richardson; Robert Schlossman; klaus podar; Nikhil C Munshi; Nicholas Mitsiades; Kenneth C Anderson
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Blood 2003;101(4):1530-4.
2003: Masaharu Akiyama; Teru Hideshima; Toshiaki Hayashi; Yu-Tzu Tai; Constantine S Mitsiades; Nicholas Mitsiades; Dharminder Chauhan; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.
Cancer research 2003;63(1):18-21.
2003: Antonia M Joussen; Vassiliki Poulaki; Nicholas Mitsiades; Wen-yi Cai; Izumi Suzuma; John Pak; Shyr-Te Ju; Susan L Rook; Peter Esser; Constantine S Mitsiades; Bernd Kirchhof; Anthony P Adamis; Lloyd Paul Aiello
Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(1):76-8.
2002: Vassiliki Poulaki; Constantine S Mitsiades; Antonia M Joussen; Alexandra Lappas; Bernd Kirchhof; Nicholas Mitsiades
Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability.
The American journal of pathology 2002;161(6):2229-40.
2002: Paul G Richardson; Robert Schlossman; Edie Weller; Teru Hideshima; Constantine S Mitsiades; Faith Davies; Richard LeBlanc; Laurence Catley; Deborah Doss; Kathleen Kelly; Mary McKenney; Julie Mechlowicz; Andrea Freeman; Reggie Deocampo; Rebecca Rich; Joan J Ryoo; Dharminder Chauhan; Kathe Balinski; Jerome B Zeldis; Kenneth C Anderson
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Blood 2002;100(9):3063-7.
2002: Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Steve P Treon; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(22):14374-9.
2002: Richard LeBlanc; Laurence Catley; Teru Hideshima; Suzanne Lentzsch; Constantine S Mitsiades; Nicholas Mitsiades; Donna Neuberg; Olga Goloubeva; Christine S Pien; Julian Adams; Deepak Gupta; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Cancer research 2002;62(17):4996-5000.
2002: Constantine S Mitsiades; Nicholas Mitsiades; Vassiliki Poulaki; Robert Schlossman; Masaharu Akiyama; Dharminder Chauhan; Teru Hideshima; Steve P Treon; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Oncogene 2002;21(37):5673-83.
2002: Vassiliki Poulaki; Constantine S Mitsiades; Vassiliki Kotoula; Sofia Tseleni-Balafouta; Avi Ashkenazi; Demetrios A Koutras; Nicholas Mitsiades
Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
The American journal of pathology 2002;161(2):643-54.
2002: Deepak Gupta; klaus podar; Yu-Tzu Tai; Boris Lin; Teru Hideshima; Masaharu Akiyama; Richard LeBlanc; Laurence Catley; Nicholas Mitsiades; Constantine S Mitsiades; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
Experimental hematology 2002;30(7):711-20.
2002: Masaharu Akiyama; Teru Hideshima; Toshiaki Hayashi; Yu-Tzu Tai; Constantine S Mitsiades; Nicholas Mitsiades; Dharminder Chauhan; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Cytokines modulate telomerase activity in a human multiple myeloma cell line.
Cancer research 2002;62(13):3876-82.
2002: Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Paul G Richardson; Teru Hideshima; Nikhil C Munshi; Steve P Treon; Kenneth C Anderson
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Blood 2002;99(12):4525-30.
2002: Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Paul G Richardson; Teru Hideshima; Nikhil C Munshi; Steve P Treon; Kenneth C Anderson
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
Blood 2002;99(11):4079-86.
2002: Teru Hideshima; Dharminder Chauhan; Paul Richardson; Constantine S Mitsiades; Nicholas Mitsiades; Toshiaki Hayashi; Nikhil C Munshi; Lenny Dang; Alfredo Castro; Vito J Palombella; Julian Adams; Kenneth C Anderson
NF-kappa B as a therapeutic target in multiple myeloma.
The Journal of biological chemistry 2002;277(19):16639-47.
2002: Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Kenneth C Anderson; Steve P Treon
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
Blood 2002;99(6):2162-71.
2002: Michael Koutsilieris; Constantine S Mitsiades; Theodoros Dimopoulos; John Vacalicos; Theocharis Lambou; Athanassios Tsintavis; Constantine Milathianakis; John Bogdanos; Dimitrios Karamanolakis
Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.
Expert opinion on investigational drugs 2002;11(2):283-93.
2002: Steve P Treon; Linda M Pilarski; Andrew R Belch; Abigail Kelliher; Frederic Preffer; Yoshihito Shima; Constantine S Mitsiades; Nicholas Mitsiades; Agnieszka Szczepek; Leonard Ellman; David Harmon; Michael L Grossbard; Kenneth C Anderson
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(1):72-81.
2001: Michael Koutsilieris; Constantine S Mitsiades; Theodoros Dimopoulos; Anastassios Ioannidis; A Ntounis; Theocharis Lambou
A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
The Journal of clinical endocrinology and metabolism 2001;86(12):5729-36.
2001: Nicholas Mitsiades; Vassiliki Poulaki; Constantine S Mitsiades; Demetrios A Koutras; George Chrousos
Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases.
Trends in endocrinology and metabolism: TEM 2001;12(9):384-90.
2001: Antigone Sourla; PANAGIOTIS E. LEMBESSIS; Constantine S Mitsiades; Theodoros Dimopoulos; M Skouteris; M Metsinis; A Ntounis; Anastassios Ioannidis; A Katsoulis; V Kyragiannis; Theocharis Lambou; Athanassios Tsintavis; Michael Koutsilieris
Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients.
Anticancer research 2001;21(5):3565-70.
2001: Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Kenneth C Anderson; Steve P Treon
Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
Expert opinion on investigational drugs 2001;10(8):1521-30.
2001: Constantine S Mitsiades; Steve P Treon; Nicholas Mitsiades; Y Shima; Paul Richardson; Robert Schlossman; Teru Hideshima; Kenneth C Anderson
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Blood 2001;98(3):795-804.
2001: klaus podar; Yu-Tzu Tai; Faith E Davies; Suzanne Lentzsch; Martin Sattler; Teru Hideshima; Boris K Lin; Deepak Gupta; Y Shima; Dharminder Chauhan; Constantine S Mitsiades; Noopur Raje; Paul Richardson; Kenneth C Anderson
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Blood 2001;98(2):428-35.
2001: Constantine S Mitsiades; Michael Koutsilieris
Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer.
Expert opinion on investigational drugs 2001;10(6):1099-115.
2001: Nicholas Mitsiades; Vassiliki Poulaki; Constantine S Mitsiades; Kenneth C Anderson
Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
Expert opinion on investigational drugs 2001;10(6):1075-84.
2001: Steve P Treon; Constantine S Mitsiades; Nicholas Mitsiades; Gloria Young; Deborah Doss; Robert Schlossman; Kenneth C Anderson
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(3):263-71.
2000: Constantine S Mitsiades; Antigone Sourla; Charles Doillon; PANAGIOTIS E. LEMBESSIS; Michael Koutsilieris
Three-dimensional type I collagen co-culture systems for the study of cell-cell interactions and treatment response in bone metastases.
Journal of musculoskeletal & neuronal interactions 2000;1(2):153-5.
2000: Michael Koutsilieris; Constantine S Mitsiades; PANAGIOTIS E. LEMBESSIS; Antigone Sourla
Cancer and bone repair mechanism: clinical applications for hormone refractory prostate cancer.
Journal of musculoskeletal & neuronal interactions 2000;1(1):15-7.
2000: Michael Koutsilieris; Constantine S Mitsiades; Antigone Sourla
Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer.
Molecular medicine (Cambridge, Mass.) 2000;6(4):251-67.